Back to search results

Fast TILs for Metastatic Pleural Effusions or Mesothelioma

This study is testing a new immunotherapy called Fast TIL, an adoptive cellular therapy (ACT), to treat cancer that has spread to the lining of the lungs (pleura) or malignant mesothelioma. The ACT product is made from your own immune cells (T-cells) taken from your pleural fluid. These cells are grown in a lab and then given back to you through a catheter in your chest, along with a drug called Interleukin-2 (IL-2). The goal is to see if this treatment is safe and effective in fighting the cancer and relieving symptoms. You would need to have symptomatic, biopsy-proven malignant disease to the pleura or mesothelioma, and have already tried standard treatments that didn't work. The study plans to enroll 10 participants between 18 and 79 years old.

Study design
This is a first-in-human study, meaning it's the first time this specific treatment is being tested in people. It is an interventional study, and the planned enrollment is 10 participants.
What's involved
Your pleural fluid will be collected to create the ACT product. Before receiving the ACT product, you will have outpatient chemotherapy. The ACT product and IL-2 will be given through a pleural catheter.
Compensation
Not stated in the trial record.
Follow-up
The feasibility of manufacturing the ACT product will be measured at 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07443020

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Recruiting
PHASE1Ages 18–79InterventionalTreatment
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
~10 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:locally manufactured adoptive cellular therapy (ACT) productInterleukin-2 (IL-2)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device
Measured over 30 days
+3 more outcomes measured

Conditions

Malignant Pleural Effusion
Malignant Mesothelioma
Pleural Effusion, Malignant
Metastasis to Pleura

Explore related trials

Malignant MesotheliomaMalignant Pleural Effusion

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Patrick Wagner, MD · PRINCIPAL_INVESTIGATOR · Allegheny Health Network

Who to contact

Patrick Wagner, MD
[email protected]
412-359-3731
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device30 days

    flow cytometry for cellular ACT identity

  • Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device30 days

    cytotoxicity assays for ACT potency

  • Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device30 days

    flow cytometry for cellular ACT purity

  • To demonstrate the safety of intrapleural administration of the locally manufactured ACT product plus Interleukin 2 (IL-2) to study patients5 years

    incidence of Treatment-Emergent Adverse Events (Safety) of intrapleural administration of the locally manufactured ACT product, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.